Researchers develop method for identifying aggressive breast cancer drivers

Precision cancer medicine requires personalized biomarkers to identify patients who will benefit from specific cancer therapies. In an effort to improve the accuracy of predictions about prognosis for patients with breast cancer and the efficacy of personalized therapy, University of North Carolina Lineberger Comprehensive Cancer Center researchers have developed a method to precisely identify individual patients who have aggressive breast […]

Continue reading »

Targeting cell division in pancreatic cancer

Pancreatic cancer is one of the deadliest cancers, with patients surviving on average less than a year once the disease has spread. There is an urgent need to evaluate more therapeutic targets. The chemotherapeutic agent abemaciclib is effective in treating breast cancer, but there is limited preclinical evaluation of this targeted therapy in treating pancreatic cancer. New research from Sidney […]

Continue reading »

Using math to help treat Alzheimer’s, Parkinson’s and other diseases

Protein aggregation—in which misfolded proteins clump together to form large fibrils—has been implicated in many diseases including Alzheimer’s, Parkinson’s, and type II diabetes. While the exact role these fibrils play in diseases isn’t fully understood, many of the current treatments for diseases like Alzheimer’s and Parkinson’s target the aggregation process. However, finding the right treatment protocols for these drugs, which […]

Continue reading »

ACIP recommends catch-up HPV vaccines through age 26

(HealthDay)—Catch-up human papillomavirus (HPV) vaccinations are recommended for all persons through age 26 years and should be considered for some persons aged 27 to 45 years, according to research published in the Aug. 16 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report. Noting that HPV vaccination is recommended at age 11 or 12 […]

Continue reading »

MDM2 counteracts resistance to CDK4/6 inhibitors for melanoma therapy

A study from Vanderbilt-Ingram Cancer Center and the Department of Veterans Affairs led by Anna Vilgelm, MD, Ph.D., and Ann Richmond, Ph.D., has identified a possible second-line treatment for melanoma patients. The potential treatment would render CDK4/6 inhibitors, a class of drugs prescribed for some breast cancers, also effective against melanoma by combining the inhibitors with MDM2 compounds, which are […]

Continue reading »
1 51 52 53 54 55 202